Table 4.
NAPSI, BUNES and GUESS values in patients with psoriatic disease receiving systemic therapy.
| Parameters | PSO (n = 35) |
PSA (n = 154) |
p Value | cDMARDs (n = 94) |
bDMARDs (n = 29) |
Combined Therapy (n = 18) |
p Value |
|---|---|---|---|---|---|---|---|
| High NAPSI (≥20) | 21 (60%) | 72 (46.8%) | 0.157 | 44 (46.8%) | 15 (51.7%) | 7 (38.9%) | 0.693 |
| Low NAPSI (<20) | 14 (40%) | 82 (53.2%) | 0.157 | 50 (53.2%) | 14 (48.3%) | 11 (61.1%) | 0.693 |
| High BUNES (≥22) | 21 (60%) | 74 (48.1%) | 0.168 | 51 (54.3%) | 16 (55.2%) | 7 (38.9%) | 0.416 |
| Low BUNES (<22) | 13 (37.1%) | 78 (50.6%) | 0.168 | 42 (44.7%) | 12 (41.4%) | 11 (61.1%) | 0.416 |
| High GUESS (≥3) | 12 (34.3%) | 82 (53.2%) | 0.030 | 60 (63.8%) | 26 (89.7%) | 10 (55.6%) | 0.021 |
| Low GUESS (<3) | 23 (65.7%) | 68 (44.2%) | 0.030 | 31 (33.0%) | 3 (10.3%) | 8 (44.4%) | 0.021 |
PsO, psoriasis; PsA, psoriatic arthritis; n, number of patients; cDMARDs, only conventional disease-modifying antirheumatic drugs; bDMARDs, only biological disease-modifying antirheumatic drugs; Combined therapy, cDMARDs plus bDMARDs; GUESS, Glasgow Ultrasound Enthesitis Scoring System; NAPSI, nail psoriasis severity index; BUNES, Brown University Nail Enthesis Scale.